Mesoblast (NASDAQ:MESO) Stock Price Down 3.4% – What’s Next?

Mesoblast Limited (NASDAQ:MESO) shares fell 3.4% during mid-day trading on Tuesday . The company traded as low as $18.10 and last traded at $18.32. 102,181 shares were traded during mid-day trading, a decline of 72% from the average session volume of 360,621 shares. The stock had previously closed at $18.96.

Wall Street Analysts Forecast Growth

Several research analysts have recently commented on MESO shares. Jefferies Financial Group lowered Mesoblast from a “buy” rating to a “hold” rating in a report on Monday, December 23rd. Maxim Group raised shares of Mesoblast from a “hold” rating to a “buy” rating and set a $12.00 target price on the stock in a research note on Tuesday, September 24th. Finally, Piper Sandler increased their price target on shares of Mesoblast from $11.00 to $15.00 and gave the company an “overweight” rating in a research note on Thursday, December 19th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and three have issued a buy rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus target price of $13.50.

Mesoblast Price Performance

The business has a fifty day moving average price of $12.73 and a two-hundred day moving average price of $9.27. The company has a current ratio of 1.18, a quick ratio of 1.18 and a debt-to-equity ratio of 0.21.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of the stock. Signaturefd LLC lifted its holdings in shares of Mesoblast by 128.7% in the 3rd quarter. Signaturefd LLC now owns 5,506 shares of the company’s stock worth $45,000 after acquiring an additional 3,099 shares during the last quarter. Perkins Coie Trust Co increased its holdings in Mesoblast by 15.0% in the 3rd quarter. Perkins Coie Trust Co now owns 11,500 shares of the company’s stock valued at $94,000 after purchasing an additional 1,500 shares during the last quarter. Rathbones Group PLC purchased a new stake in Mesoblast in the second quarter valued at approximately $95,000. XTX Topco Ltd acquired a new position in Mesoblast during the second quarter worth $103,000. Finally, GAMMA Investing LLC boosted its position in shares of Mesoblast by 22.1% during the fourth quarter. GAMMA Investing LLC now owns 6,711 shares of the company’s stock worth $133,000 after buying an additional 1,213 shares during the period. Hedge funds and other institutional investors own 1.43% of the company’s stock.

About Mesoblast

Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells.